Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334443 | 0.91 | ALDH1A1 (0.55) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| Acetonitrile SCHEMBL10703316 | 0.91 | LMNA (0.53) | LMNACYP1A2AGTR1CA12CA1 | |
| Acetaldehyde SCHEMBL10704170 | 0.91 | LMNA (0.53) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL29120476 | 0.83 | LMNA (0.58) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL10639362 | 0.83 | LMNA (0.58) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL1496733 | 0.83 | LMNA (0.68) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL7415697 | 0.83 | LMNA (0.58) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL8684485 | 0.83 | LMNA (0.58) | LMNACYP1A2AGTR1CA12CA1 | |
| SCHEMBL5080663 | 0.83 | ALOX15 (0.56) | LMNACYP1A2AGTR1KDM4EL3MBTL1 | |
| SCHEMBL6123816 | 0.82 | IDO1 (0.50) | LMNACYP1A2AGTR1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-108601958-B | Pro-fragrance compositions | 爱客多有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-1724013-B1 | ASYMMETRIC REACTION CATALYST AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS WITH THE SAME | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-7910762-B2 | mixing a pentavalent niobium compound and a tetraol having an optically active binapthol; catalysts for the following asymmetric reactions: Mannich, epoxide ring opening, allylation, cyanation, and alkylation; reacting silicon enolate with imine to form beta-aminocarbonyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7667078-B2 | Asymmetric reaction catalyst and method for preparing optically active compound using the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20100029968-A1 | ASYMMETRIC REACTION CATALYST AND METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND USING THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070265472-A1 | Asymmetric Reaction Catalyst and Method for Preparing Optically Active Compound Using the Same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-11-15 | — | — | US | disclosed |
| WO-2007076161-A2 | COMPOUNDS WITH THERAPEUTIC ACTIVITY | MYRIAD GENETICS, INC (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1724013-A1 | ASYMMETRIC REACTION CATALYST AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS WITH THE SAME | Japan Science and Technology Agency (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | LMNA 3909/4885CYP1A2 4647/4885AGTR1 842/4885 |
| US-20100029968-A1 | ASYMMETRIC REACTION CATALYST AND METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND USING THE SAME | SQLE, DNTT, TDO2 | LMNA 4402/4885CYP1A2 495/4885AGTR1 1899/4885 |
| US-20070265472-A1 | Asymmetric Reaction Catalyst and Method for Preparing Optically Active Compound Using the Same | SQLE, TDO2, DNTT | LMNA 4206/4885CYP1A2 362/4885AGTR1 1667/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | LMNA 3643/4885CYP1A2 587/4885AGTR1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.